San Francisco-based Breast Cancer Action wanted its message, “Eli Lilly is making us sick. Tell them to stop,” posted on local billboards. But numerous sign companies refused, the group said.
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
In the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay
for any breast cancer patient to stay two days in a hospital after surgery.
Stimulus dollars from the National Institutes of Health expected to spark 30 to 40 new research jobs by 2013.
Almost eight months ago, I used this space to share the new perspective on life I discovered as a side effect of my battle
with cancer. A lot has happened since then, and I’m still marveling at the difference—even as I struggle to hold
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
Under the current proposal, the same type of groups that made the CDC’s recommendations will outline guidelines about which treatment will be offered under a government program.
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
Cook Medical has split its interventional devices business into two units, pulling its lesser known cancer products out from under the shadow of its heart products.
Eli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now
the best-selling class of drugs in the world and one of the fastest growing.